The "connection" between HIV drug resistance and RNase H

29Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

Currently, nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) are two classes of antiretroviral agents that are approved for treatment of HIV-1 infection. Since both NRTIs and NNRTIs target the polymerase (pol) domain of reverse transcriptase (RT), most genotypic analysis for drug resistance is limited to the first -300 amino acids of RT. However, recent studies have demonstrated that mutations in the C-terminal domain of RT, specifically the connection subdomain and RNase H domain, can also increase resistance to both NRTIs and NNRTIs. In this review we will present the potential mechanisms by which mutations in the C-terminal domain of RT influence NRTI and NNRTI susceptibility, summarize the prevalence of the mutations in these regions of RT identified to date, and discuss their importance to clinical drug resistance. © 2010 by the authors.

Cite

CITATION STYLE

APA

Delviks-Frankenberry, K. A., Nikolenko, G. N., & Pathak, V. K. (2010, July). The “connection” between HIV drug resistance and RNase H. Viruses. https://doi.org/10.3390/v2071476

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free